Patents by Inventor Susan D. Hellmann

Susan D. Hellmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT WITH ANTI ErbB2 ANTIBODIES
    Publication number: 20140341886
    Abstract: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin. The invention further provides a method of treating cancer in a human patient comprising administering effective amounts of an anti-ErbB2 antibody and a cardioprotectant to the patient.
    Type: Application
    Filed: December 26, 2013
    Publication date: November 20, 2014
    Applicant: Genentech, Inc.
    Inventor: Susan D. Hellmann
  • Treatment with anti-ErbB2 antibodies
    Patent number: 8642036
    Abstract: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin. The invention further provides a method of treating cancer in a human patient comprising administering effective amounts of an anti-ErbB2 antibody and a cardioprotectant to the patient.
    Type: Grant
    Filed: August 2, 2004
    Date of Patent: February 4, 2014
    Assignee: Genentech, Inc.
    Inventor: Susan D. Hellmann
  • Treatment with anti-ErbB2 antibodies
    Patent number: 8425908
    Abstract: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin. The invention further provides a method of treating cancer in a human patient comprising administering effective amounts of an anti-ErbB2 antibody and a cardioprotectant to the patient.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: April 23, 2013
    Assignee: Genentech, Inc.
    Inventor: Susan D. Hellmann
  • Treatment with anti-ErbB2 antibodies
    Patent number: 8309087
    Abstract: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin. The invention further provides a method of treating cancer in a human patient comprising administering effective amounts of an anti-ErbB2 antibody and a cardioprotectant to the patient.
    Type: Grant
    Filed: May 9, 2011
    Date of Patent: November 13, 2012
    Assignee: Genentech, Inc.
    Inventor: Susan D. Hellmann
  • TREATMENT WITH ANTI-ErbB2 ANTIBODIES
    Publication number: 20120034213
    Abstract: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin. The invention further provides a method of treating cancer in a human patient comprising administering effective amounts of an anti-ErbB2 antibody and a cardioprotectant to the patient.
    Type: Application
    Filed: July 18, 2011
    Publication date: February 9, 2012
    Inventor: Susan D. Hellmann
  • Treatment with anti-ErbB2 antibodies
    Patent number: 8075892
    Abstract: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin. The invention further provides a method of treating cancer in a human patient comprising administering effective amounts of an anti-ErbB2 antibody and a cardioprotectant to the patient.
    Type: Grant
    Filed: July 20, 2007
    Date of Patent: December 13, 2011
    Assignee: Genentech, Inc.
    Inventor: Susan D. Hellmann
  • Treatment with Anti-ErbB2 Antibodies
    Publication number: 20110250194
    Abstract: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin. The invention further provides a method of treating cancer in a human patient comprising administering effective amounts of an anti-ErbB2 antibody and a cardioprotectant to the patient.
    Type: Application
    Filed: May 9, 2011
    Publication date: October 13, 2011
    Inventor: Susan D. Hellmann
  • Treatment with anti-ErbB2 antibodies
    Patent number: 7892549
    Abstract: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin.
    Type: Grant
    Filed: February 3, 2003
    Date of Patent: February 22, 2011
    Assignee: Genentech, Inc.
    Inventors: Virginia E. Paton, Steven Shak, Susan D. Hellmann
  • Treatment with anti-ErbB2 antibodies
    Patent number: 7846441
    Abstract: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin.
    Type: Grant
    Filed: December 10, 1998
    Date of Patent: December 7, 2010
    Assignee: Genentech, Inc.
    Inventor: Susan D. Hellmann
  • TREATMENT WITH ANTI-ERBB2 ANTIBODIES
    Publication number: 20080187533
    Abstract: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin. The invention further provides a method of treating cancer in a human patient comprising administering effective amounts of an anti-ErbB2 antibody and a cardioprotectant to the patient.
    Type: Application
    Filed: January 4, 2008
    Publication date: August 7, 2008
    Applicant: Genentech, Inc.
    Inventor: Susan D. Hellmann
  • Treatment with anti-ErbB2 antibodies
    Publication number: 20040037823
    Abstract: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin.
    Type: Application
    Filed: February 3, 2003
    Publication date: February 26, 2004
    Applicant: Genentech, Inc.
    Inventors: Virginia E. Paton, Steven Shak, Susan D. Hellmann
  • Treatment with anti-ErbB2 antibodies
    Publication number: 20030170234
    Abstract: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin. The invention further provides a method of treating cancer in a human patient comprising administering effective amounts of an anti-ErbB2 antibody and a cardioprotectant to the patient.
    Type: Application
    Filed: April 4, 2003
    Publication date: September 11, 2003
    Applicant: GENENTECH, INC.
    Inventor: Susan D. Hellmann
  • Treatment with anti-ErbB2 antibodies
    Publication number: 20030147884
    Abstract: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin.
    Type: Application
    Filed: February 3, 2003
    Publication date: August 7, 2003
    Applicant: Genentech, Inc.
    Inventors: Virginia E. Paton, Steven Shak, Susan D. Hellmann